Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference
2024年1月31日 - 10:00PM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a
commercial-stage biopharmaceutical company focused on developing
meaningful innovations in immuno-dermatology, today announced that
Arcutis management will participate in the Guggenheim Healthcare
Talks – 6th Annual Biotechnology Conference.
Details for the company’s participation are as follows:
Fireside Chat
Date: Wednesday, February 7, 2024Fireside
Chat Time: 10:00 am ET
The webcast for this conference may be accessed at the “Events”
section of the Company’s website. A replay of the webcast will be
available on the Arcutis website for 180 days following the
conference.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is a commercial-stage medical dermatology company
that champions meaningful innovation to address the urgent needs of
individuals living with immune-mediated dermatological diseases and
conditions. With a commitment to solving the most persistent
patient challenges in dermatology, Arcutis has a growing portfolio
including two FDA approved products that harness our unique
dermatology development platform coupled with our dermatology
expertise to build differentiated therapies against biologically
validated targets. Arcutis’ dermatology development platform
includes a robust pipeline with multiple clinical programs for a
range of inflammatory dermatological conditions including scalp and
body psoriasis, atopic dermatitis, and alopecia areata. For more
information, visit www.arcutis.com or follow Arcutis on
LinkedIn, Facebook, and X.
Forward-Looking StatementsThis press release
contains “forward-looking” statements, including, among others,
statements regarding its potential to address urgent needs and
expectations with regard to the timing of data and regulatory
events. These statements involve substantial known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance, or achievements to be
materially different from the information expressed or implied by
these forward-looking statements and you should not place undue
reliance on our forward-looking statements. Risks and uncertainties
that may cause our actual results to differ include risks inherent
in the clinical development process and regulatory approval
process, the timing of regulatory filings, the timing and expenses
of commercialization efforts, and our ability to defend our
intellectual property. For a further description of the risks and
uncertainties applicable to our business, see the “Risk Factors”
section of our Form 10-K filed with U.S. Securities and Exchange
Commission (SEC) on February 28, 2023, as well as any subsequent
filings with the SEC. You should not place undue reliance on any
forward-looking statements in this press release. We undertake no
obligation to revise or update information herein to reflect events
or circumstances in the future, even if new information becomes
available. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Contacts:
MediaAmanda Sheldon, Head of Corporate
Communicationsasheldon@arcutis.com
InvestorsDerek ColeInvestor Relations Advisory
Solutionsderek.cole@iradvisory.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
過去 株価チャート
から 4 2024 まで 5 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
過去 株価チャート
から 5 2023 まで 5 2024